Anthropic has announced the establishment of a research laboratory in the San Francisco Bay Area where it will carry out physical experiments to complement its artificial intelligence work. The facility is part of the company’s life sciences efforts and is intended to enable laboratory testing that cannot be performed purely in silico.
Company statements and rationale
Eric Kauderer-Abrams, head of Anthropic’s life sciences division, told Reuters that while AI can accelerate many steps of biological research, ultimate testing in real laboratories will still be necessary for the foreseeable future. He said the laboratory work will be done primarily in-house, though outside partners may be engaged when needed.
Kauderer-Abrams also emphasized that Anthropic is still early in developing the practical tools for biological research and that human oversight will be fundamental in laboratory operations to ensure safety.
Link to the Claude Science program and research focus
Anthropic launched a drug-research program called Claude Science in June. The company has not disclosed exact details of the projects that will be conducted in the new lab, but the timing suggests the facility will support Claude Science activities.
Anthropic said it is particularly interested in pursuing research that traditional pharmaceutical companies are unlikely to take on because it would not be commercially attractive. At the same time, a company representative told Reuters that drug development is not the only reason for opening the lab; the facility will support a broader range of research goals.
Automation and laboratory robotics
Sources speaking to Reuters indicated that Anthropic is working on robots capable of performing scientific experiments. Kauderer-Abrams clarified that the company is still at an early stage in this area and that human supervision will remain essential for laboratory work to maintain safety.
Significance
The move reflects a broader trend of integrating AI-driven tools and automation into biological and medical research to speed up work on complex problems and to tackle investigations that the traditional pharmaceutical sector may avoid. Anthropic’s new lab and its Claude Science program signal increasing convergence between AI companies and life sciences research.
